CCN3 and breast cancer: Recent evidence suggests that bone metastatic breast cancer cells can reprogram osteoblasts in the bone marrow niche to produce altered amounts of decorin and CCN3, which leads to the inhibition of tumor cell proliferation via upregulation of p21 expression.